Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Invenomic Capital Management. This analysis is provided for institutional research purposes only and is not investment advice.
"Document contains only performance data and regulatory disclosures with no investment commentary or strategic insights provided."
This document contains only performance data and fund disclosures for the Invenomic Fund as of September 30, 2023. The fund generated a year-to-date return of 14.13%, outperforming both the S&P 1500 Index (12.24%) and significantly outperforming the Russell 1000 Value/Growth Index (-19.25%). The fund was launched on June 19, 2017, and carries total operating expenses of 2.93% gross and 2.23% after expense cap for Class I shares. A 1.00% redemption fee applies to shares sold within 60 days. No investment commentary, portfolio positioning, market outlook, or strategic insights are provided in this performance summary. The document serves purely as a regulatory disclosure and performance reporting vehicle, containing standard disclaimers about past performance not guaranteeing future results and the need to read the prospectus carefully before investing.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
Growth Outlook
Risk Appetite
Capital Deployment
Forward Guidance
Language Signal
Perceived Risk
Opportunity Density
Time Horizon